临床药师参与一例重组人白介素-11致患者心律失常的药学实践  

Clinical pharmacists involved in the pharmaceutical practice of a case of arrhythmia caused by rhIL-11

作　　者：彭艺飞 周蔚[1] 李佳霖[1] PENG Yi-fei;ZHOU Wei;LI Jia-lin(Leshan Hospital of Traditional Chinese Medicine,Leshan 614000,China)

机构地区：[1]乐山市中医医院,四川乐山614000

出　　处：《中国处方药》2022年第8期69-71,共3页Journal of China Prescription Drug

基　　金：四川省乐山市科技局基金项目(20ZDYJ0108)。

摘　　要：本文叙述了临床药师参与1例肿瘤患者因骨髓抑制入院后治疗过程中出现心律失常的药学监护过程。临床药师根据患者自身疾病情况进行分析,梳理患者入院后的用药记录,对疑似引起心律失常的药物进行重整,并采用药品不良反应判断表进行评分,推断出使用重组人白介素-11是导致该患者本次治疗期间出现心律失常的主要原因。临床药师对该类患者使用药物提出有效建议,在保证临床安全用药的同时,为患者提供安全可行的药学监护。This paper describes the pharmaceutical care process in which a clinical pharmacist participated in the treatment of heart rate disorder in a tumor patient after admission due to myelosuppression.Clinical pharmacists analyzed the patient's own disease,combed the patient's medication record after admission,reorganized the drug suspected to cause arrhythmia,and scored it with the drug adverse reaction judgment table,and concluded that the use of rhIL-11 was the main cause of arrhythmia in this treatment period.Clinical pharmacists put forward effective suggestions on the use of drugs for such patients,which can ensure the clinical safety of drug use and provide safe and feasible pharmaceutical care for patients.

关 键 词：重组人白介素-11 不良反应 心律失常 临床药师 药学监护 

分 类 号：R969.3[医药卫生—药理学]